Enlivex Therapeutics Enrolls First 10 Patients in Phase II Trial
Ticker: ENLV · Form: 6-K · Filed: Nov 12, 2024 · CIK: 1596812
Sentiment: neutral
Topics: clinical-trial, phase-ii, drug-development
TL;DR
Enlivex hits Phase II patient enrollment target, trial moving forward.
AI Summary
Enlivex Therapeutics Ltd. announced on November 12, 2024, the enrollment and dosing of the first 10 patients in the Phase II stage of its clinical trial for its drug candidate. This marks a significant step in the development of their therapeutic.
Why It Matters
This milestone indicates progress in Enlivex's clinical development pipeline, potentially moving their drug candidate closer to market approval and patient availability.
Risk Assessment
Risk Level: medium — Clinical trial progress is a positive step, but the outcome of Phase II trials is inherently uncertain and carries significant risk.
Key Numbers
- 10 — Patients Enrolled (First patients enrolled in the Phase II stage of the clinical trial.)
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- November 12, 2024 (date) — Announcement Date
FAQ
What is the specific drug candidate being tested in the Phase II trial?
The filing does not specify the name of the drug candidate being tested in the Phase II trial.
What is the indication or disease this Phase II trial is targeting?
The filing does not specify the indication or disease being targeted by this Phase II trial.
What is the total number of patients planned for enrollment in the Phase II trial?
The filing does not state the total number of patients planned for enrollment in the Phase II trial.
What is the expected timeline for the completion of the Phase II trial?
The filing does not provide an expected timeline for the completion of the Phase II trial.
Has Enlivex Therapeutics Ltd. previously filed a Form 6-K for this month?
This filing is the first Form 6-K filed by Enlivex Therapeutics Ltd. for the month of November 2024.
Filing Stats: 231 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2024-11-12 08:18:42
Filing Documents
- ea0220658-6k_enlivex.htm (6-K) — 10KB
- ea022065801ex99-1_enlivex.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-096258.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Title: Oren Hershkovitz Chief Executive Officer Date: November 12, 2024 2